troglitazone has been researched along with orlistat in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Auld, DS; Austin, CP; Huang, R; Moeller, TA; Sakamuru, S; Shinn, P; Shukla, SJ; Vanleer, D; Xia, M | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Noda, M | 1 |
| Bouche, C; Goldfine, AB | 1 |
| Anderson, DC | 1 |
| Laakso, M | 1 |
| Moreno Sánchez, D | 1 |
7 review(s) available for troglitazone and orlistat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Primary prevention of diabetes mellitus by pharmacological intervention].
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lactones; Metformin; Orlistat; Pravastatin; Primary Prevention; Ramipril; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Prevention of type 2 diabetes: are we ready?
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Life Style; Lipase; Metformin; Orlistat; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Pharmacologic prevention or delay of type 2 diabetes mellitus.
Topics: Acarbose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Meta-Analysis as Topic; Metformin; Orlistat; Randomized Controlled Trials as Topic; Thiazolidinediones; Troglitazone | 2005 |
Prevention of type 2 diabetes.
Topics: Acarbose; Birth Weight; Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Environment; Exercise; Female; Finland; Humans; Hypertension; Lactones; Life Style; Male; Obesity; Orlistat; Risk Factors; Thiazolidinediones; Time Factors; Troglitazone | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
5 other study(ies) available for troglitazone and orlistat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of clinically used drugs that activate pregnane X receptors.
Topics: Animals; Cell Line, Tumor; Cytochrome P-450 CYP3A; Drug Interactions; Hep G2 Cells; Hepatocytes; Humans; Pharmaceutical Preparations; Pregnane X Receptor; Rats; Receptors, Steroid; Small Molecule Libraries; Species Specificity; Structure-Activity Relationship; Xenobiotics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |